# Real-world Study for Patients With Advanced Hepatobiliary Tumors

> **NCT03892577** · — · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 3000 (estimated)

## Conditions studied

- Objective Response Rate
- Progression-free Survival
- Overall Survival
- Disease Control Rate
- Duration of Response
- Five-year Survival Rate
- Quality of Life

## Interventions

- **DRUG:** Precision oncology including targeted therapy and immunotherapy

## Key facts

- **NCT ID:** NCT03892577
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2023-10-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03892577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03892577, "Real-world Study for Patients With Advanced Hepatobiliary Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03892577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*